Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a.
Franziska RinkerCorinna M BremerKathrin SchröderSteffen B WiegandBirgit BremerMichael P MannsAnke R M KraftHeiner WedemeyerLei YangVedran PavlovicCynthia WatWolfram H GerlichDieter GlebeMarkus CornbergPublished in: Liver international : official journal of the International Association for the Study of the Liver (2019)
Hepatitis B surface protein levels differ by HBV genotype. However, quantification of HBs proteins has no advantage over the already established HBsAg assays to predict response to peginterferon alfa-2a therapy in HBeAg-positive patients.
Keyphrases
- hepatitis b virus
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- replacement therapy
- liver failure
- ms ms
- peritoneal dialysis
- liquid chromatography tandem mass spectrometry
- small molecule
- high performance liquid chromatography
- protein protein
- patient reported outcomes
- amino acid
- binding protein
- simultaneous determination